HLA-A2-expressing Drosophila stimulator cell (Drosophila aAPC)

HLA-A2-expressing Drosophila stimulator cells are a specialized type of artificial antigen-presenting cell (aAPC) derived from the Drosophila melanogaster S2 cell line (Sun et al., 1996, Nature). These cells are genetically engineered to express human leukocyte antigen (HLA) molecules, specifically the HLA-A2 subtype, along with essential co-stimulatory molecules such as B7-1 (CD80) and ICAM-1 (CD54) (Sprent et al., 1997, Journal of Experimental Medicine). By loading these cells with specific melanoma-derived peptides, such as those from MART-1, gp100, or Tyrosinase, they can be used to selectively activate and expand tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) from a patient's peripheral blood (Latouche & Sadelain, 2000, Nature Medicine). This technology is primarily utilized in the context of adoptive cell therapy for melanoma, where the goal is to generate a large population of potent, tumor-reactive T cells ex vivo for re-infusion into the patient. While highly effective for T-cell priming due to the lack of endogenous MHC molecules in insect cells, their use is generally restricted to ex vivo applications to avoid immune reactions against the xenogeneic Drosophila proteins (PubMed ID: 8662505). The system provides a controlled environment for T-cell stimulation, allowing for the precise manipulation of the immune response against specific cancer antigens.

Other names

Drosophila S2 artificial antigen-presenting cellHLA-A2.1-expressing Drosophila melanogaster S2 cellaAPCFly-cell stimulator

Presentation of peptide-MHC complexes and co-stimulatory signals to CD8+ T cells to induce antigen-specific activation and expansion.